Cargando…

Stem Cell Therapy in Critical Limb Ischemia

Critical limb ischemia (CLI), a serious outcome of peripheral artery disease, is frequently associated with morbid outcomes. The available treatment modalities do not provide satisfactory results, leading to marked morbidities such as joint contracture and amputations, resulting in a high economic b...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeyaraman, Madhan, Nagarajan, Somumurthy, Maffulli, Nicola, R.P, Packkyarathinam, Jeyaraman, Naveen, N, Arulkumar, Khanna, Manish, Yadav, Sankalp, Gupta, Ashim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416751/
https://www.ncbi.nlm.nih.gov/pubmed/37575721
http://dx.doi.org/10.7759/cureus.41772
_version_ 1785087852581748736
author Jeyaraman, Madhan
Nagarajan, Somumurthy
Maffulli, Nicola
R.P, Packkyarathinam
Jeyaraman, Naveen
N, Arulkumar
Khanna, Manish
Yadav, Sankalp
Gupta, Ashim
author_facet Jeyaraman, Madhan
Nagarajan, Somumurthy
Maffulli, Nicola
R.P, Packkyarathinam
Jeyaraman, Naveen
N, Arulkumar
Khanna, Manish
Yadav, Sankalp
Gupta, Ashim
author_sort Jeyaraman, Madhan
collection PubMed
description Critical limb ischemia (CLI), a serious outcome of peripheral artery disease, is frequently associated with morbid outcomes. The available treatment modalities do not provide satisfactory results, leading to marked morbidities such as joint contracture and amputations, resulting in a high economic burden. The peripheral vascular disease tends to cause more morbidity in patients with diabetes and atherosclerosis, given the pre-existing compromised perfusion of medium and small vessels in diabetic patients. With surgical procedures, the chance of vascular compromise further increases, inducing a significantly greater rate of amputation. Hence, the need for nonsurgical treatment modalities such as stem cell therapy (SCT), which promotes angiogenesis, is warranted. In CLI, SCT acts through neovascularization and the development of collateral arteries, which increases blood supply to the soft tissues of the ischemic limb, providing satisfactory outcomes. An electronic database search was performed in PubMed, SCOPUS, EMBASE, and ScienceDirect to identify published clinical trial data, research studies, and review articles on stem cell therapy in critical limb ischemia. The search resulted in a total of 2391 results. Duplicate articles screening resulted in 565 articles. In-depth screening of abstracts and research titles excluded 520 articles, yielding 45 articles suitable for full-text review. On review of full text, articles with overlapping and similar results were filtered, ending in 25 articles. SCT promotes arteriogenesis, and bone marrow-derived mesenchymal stromal cells produce significant effects like reduced morbidity, improved amputation-free survival (AFS ) rate, and improved distal perfusion even in "no-option" CLI patients. SCT is a promising treatment modality for CLI patients, even in those in whom endovascular and revascularization procedures are impossible. SCT assures a prolonged AFS rate, improved distal perfusion, improved walking distances, reduced amputation rates, and increased survival ratio, and is well-tolerated.
format Online
Article
Text
id pubmed-10416751
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-104167512023-08-12 Stem Cell Therapy in Critical Limb Ischemia Jeyaraman, Madhan Nagarajan, Somumurthy Maffulli, Nicola R.P, Packkyarathinam Jeyaraman, Naveen N, Arulkumar Khanna, Manish Yadav, Sankalp Gupta, Ashim Cureus Family/General Practice Critical limb ischemia (CLI), a serious outcome of peripheral artery disease, is frequently associated with morbid outcomes. The available treatment modalities do not provide satisfactory results, leading to marked morbidities such as joint contracture and amputations, resulting in a high economic burden. The peripheral vascular disease tends to cause more morbidity in patients with diabetes and atherosclerosis, given the pre-existing compromised perfusion of medium and small vessels in diabetic patients. With surgical procedures, the chance of vascular compromise further increases, inducing a significantly greater rate of amputation. Hence, the need for nonsurgical treatment modalities such as stem cell therapy (SCT), which promotes angiogenesis, is warranted. In CLI, SCT acts through neovascularization and the development of collateral arteries, which increases blood supply to the soft tissues of the ischemic limb, providing satisfactory outcomes. An electronic database search was performed in PubMed, SCOPUS, EMBASE, and ScienceDirect to identify published clinical trial data, research studies, and review articles on stem cell therapy in critical limb ischemia. The search resulted in a total of 2391 results. Duplicate articles screening resulted in 565 articles. In-depth screening of abstracts and research titles excluded 520 articles, yielding 45 articles suitable for full-text review. On review of full text, articles with overlapping and similar results were filtered, ending in 25 articles. SCT promotes arteriogenesis, and bone marrow-derived mesenchymal stromal cells produce significant effects like reduced morbidity, improved amputation-free survival (AFS ) rate, and improved distal perfusion even in "no-option" CLI patients. SCT is a promising treatment modality for CLI patients, even in those in whom endovascular and revascularization procedures are impossible. SCT assures a prolonged AFS rate, improved distal perfusion, improved walking distances, reduced amputation rates, and increased survival ratio, and is well-tolerated. Cureus 2023-07-12 /pmc/articles/PMC10416751/ /pubmed/37575721 http://dx.doi.org/10.7759/cureus.41772 Text en Copyright © 2023, Jeyaraman et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Family/General Practice
Jeyaraman, Madhan
Nagarajan, Somumurthy
Maffulli, Nicola
R.P, Packkyarathinam
Jeyaraman, Naveen
N, Arulkumar
Khanna, Manish
Yadav, Sankalp
Gupta, Ashim
Stem Cell Therapy in Critical Limb Ischemia
title Stem Cell Therapy in Critical Limb Ischemia
title_full Stem Cell Therapy in Critical Limb Ischemia
title_fullStr Stem Cell Therapy in Critical Limb Ischemia
title_full_unstemmed Stem Cell Therapy in Critical Limb Ischemia
title_short Stem Cell Therapy in Critical Limb Ischemia
title_sort stem cell therapy in critical limb ischemia
topic Family/General Practice
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416751/
https://www.ncbi.nlm.nih.gov/pubmed/37575721
http://dx.doi.org/10.7759/cureus.41772
work_keys_str_mv AT jeyaramanmadhan stemcelltherapyincriticallimbischemia
AT nagarajansomumurthy stemcelltherapyincriticallimbischemia
AT maffullinicola stemcelltherapyincriticallimbischemia
AT rppackkyarathinam stemcelltherapyincriticallimbischemia
AT jeyaramannaveen stemcelltherapyincriticallimbischemia
AT narulkumar stemcelltherapyincriticallimbischemia
AT khannamanish stemcelltherapyincriticallimbischemia
AT yadavsankalp stemcelltherapyincriticallimbischemia
AT guptaashim stemcelltherapyincriticallimbischemia